Clinical research behind LivingWell.

A clear view of the research behind LivingWell: what has been published, what comes from real-world experience, and what is still being explored.

Published · Peer reviewed

LivingWell in women treated for breast cancer.

A randomized controlled pilot trial in Germany evaluated the LivingWell app alongside usual care.

70women with breast cancer
12 weeksLivingWell + usual care versus usual care
32 / 38intervention / control participants

Over 12 weeks, the trial found statistically significant between-group improvements in anxiety, health-related quality of life, and illness perception. A benefit for depression was not demonstrated, and the between-group distress result was not statistically significant.

The study at a glance

One trial. Two care groups.

70 women treated for breast cancer, followed over 12 weeks.

32 dark-blue dots for LivingWell plus usual care, and 38 light-blue dots for usual care. Each dot represents one participant.

Each dot represents one participant.

32LivingWell + usual care
38Usual care

Change in anxiety over 12 weeks

Average reduction on the Hospital Anxiety and Depression Scale anxiety subscale (HADS-A), from baseline to week 12. Larger reductions indicate greater improvement; these are score points, not percentages.

LivingWell + usual care
32 participants
1.94 pts
Usual care
38 participants
0.53 pts
02.5 points
Heinrich et al., 2024, section 3.2 · Between-group p = 0.014. Unadjusted difference in mean reduction: 1.41 points. Group averages do not predict individual results.

What the trial found

AnxietyImprovement observed
Health-related quality of lifeImprovement observed
Illness perceptionImprovement observed
DepressionBenefit not demonstrated
DistressNot statistically significant

Between-group findings at 12 weeks. This is a categorical summary, not a chart of effect sizes.

This is evidence about the LivingWell app. It is not a trial of the complete U.S. Prosoma Health navigation and coaching program.

Study details: methods, funding & limitations

How the results were analyzed

The anxiety results use an intention-to-treat analysis with last observation carried forward. The between-group comparison at 12 weeks had p = 0.014.

Study scope and funding

This was a small, unblinded pilot trial in women with breast cancer. Findings should not be generalized to every person affected by cancer. The study was funded by Prosoma GmbH; author employment and consultancy relationships were disclosed.

Read the Wiley publication

Heinrich et al. (2024). Effects of Mobile Application-Based Cognitive Behavioral Therapy on Psychological Outcomes in Women Treated for Breast Cancer. DOI: 10.1002/pon.70003.

Observational evidence

Real-world experience with LivingWell.

Prosoma’s supplied materials describe real-world analyses involving people using LivingWell, including users supported through Techniker Krankenkasse in Germany.

These analyses explore engagement, symptom changes, and patient experience. They are distinct from randomized trials: participation and engagement may influence which patients appear in the results.

Clinical trials and real-world analyses answer different questions. These figures come from company-reported observational research and patient feedback, not a randomized comparison.

Anxiety
68%

Reported clinically significant improvement among participants with severe anxiety at baseline.

Depressive symptoms
62%

Reported clinically significant improvement among participants with severe depressive symptoms at baseline.

Recommendation
94%

Would recommend LivingWell to another person affected by cancer.

How engagement relates to reported improvement

A separate July 2023 analysis compared 503 users by the number of lessons completed. The chart below shows each group’s reported improvement rate on a common 0–100% scale.

Engagement and reported improvement

Percentage meeting the report’s criteria for clinically significant improvement.

Fewer than 10 lessons (n = 265)At least 10 lessons (n = 238)

Anxiety

Fewer than 10
28%
At least 10
34%

Depression

Fewer than 10
22%
At least 10
32%
0%100%
Prosoma, Users Engagement: Real World Data Analysis, July 2023. Observational, not randomized or peer reviewed. These results do not show that completing more lessons caused improvement.
Study details: source, population & limitations

Who was included

The analysis included selected app users with at least two optional assessment scores. It compared fewer than 10 lessons (265 users) with at least 10 lessons (238 users).

How to interpret the comparison

Selection, missing data, and differences between users may affect the results. The reports cover different populations, baseline symptom levels, and analysis sets. International results do not automatically describe U.S. outcomes.

Source

Prosoma, Users Engagement: Real World Data Analysis, July 2023, improvement table. The percentages use the report’s criteria for clinically significant improvement.

Research library

Scientific reports and conference presentations.

Alongside the peer-reviewed publication, the research collection includes conference presentations, preliminary reports, and white papers. These sources have different levels of review and answer different questions.

Six-month Polish randomized study

333women randomized · 222 intervention / 111 control

The supplied report describes a different anxiety trajectory between groups over 24 weeks (group × time p = 0.043; reported change effect size d = 0.62). A significant depression benefit was not demonstrated.

Source: Polish RCT, methods and outcomes slides. Journal publication not verified. The report’s 333 randomized participants are kept separate from the older deck’s 214-person analysis.

Preliminary findings on patient reporting

3×reported volume of patient-reported outcomes and measures

A four-week randomized study of 160 women compared LivingWell (80 participants) with online forms and paper questionnaires (80 participants).

Source: PROs & PROMs 2026 — preliminary outcomes. Per-arm reporting totals and uncertainty estimates were not supplied. This is a reporting-volume finding, not evidence of fewer emergency visits or improved survival.

Conference presentations

The 2025 WCP poster explores serious micro-games. The 2025 Würzburg presentation examines illness perception and psychological outcomes. These are conference materials, not additional journal publications.

Clinical short reports

The Polish randomized trial report describes 333 participants. The 2026 PROs and PROMs report presents preliminary findings. Journal publication has not been verified for these reports.

Engagement and medical reports

The 2023 user engagement analysis and 2024 CSS annual medical report add context on app use and research progress. They should be read with their own methods and reporting periods.

Economic white papers

The DACH and TK materials explore modeled economics. Their estimates depend on assumptions and do not establish measured U.S. savings.

In development

Ongoing research.

The supplied research portfolio includes work associated with MemorialCare and Cedars-Sinai, as well as research in Poland. Study status and reporting dates differ between the source documents and require an updated confirmation.

We do not present anticipated results as completed findings. New publications can be added here when they are available and verified.

Bring your questions to the conversation.

Explore the research and discuss an evaluation approach for your organization.

Let’s get you connected.

Email our team